GlassScriptPhysician profile
Jon P Rampton
NPI 1548269079
$12,020.34
in general payments reported to CMS, 2019-2025
50 companies · $1,779 in 2025
The $1,779 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $1,554 · 2021: $1,462 · 2022: $1,890 · 2023: $2,098 · 2024: $2,162 · 2025: $1,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,038.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,023.09 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,392.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,328.91 | 2019-2025 | |
| Novo Nordisk INC | $1,286.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $892.43 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $537.63 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $402.27 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $357.65 | 2019-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.26 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $279.09 | 2020-2025 | Verquvo, Belsomra, Vaxelis |
| Teva Pharmaceuticals USA, INC. | $274.44 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $223.68 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $216.90 | 2020-2025 | Arexvy, Penmenvy |
| Novartis Pharmaceuticals Corporation | $216.01 | 2019-2025 | |
| Lundbeck LLC | $174.14 | 2023-2025 | Rexulti |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $173.64 | 2022-2024 | |
| Exact Sciences Corporation | $163.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $131.90 | 2020-2022 | |
| Amarin Pharma, INC. | $125.41 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $115.72 | 2021-2023 | |
| Eisai INC. | $106.64 | 2020-2021 | |
| Boston Scientific Corporation | $102.23 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Sumitomo Pharma America, INC. | $85.48 | 2023-2024 | Gemtesa |
| Allergan, INC. | $81.45 | 2019-2020 | |
| Abbott Laboratories | $79.41 | 2021-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $72.61 | 2022-2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $67.40 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $65.85 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $65.42 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.28 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $62.82 | 2022 | |
| Grifols USA, LLC | $61.01 | 2019-2020 | |
| Astellas Pharma US INC | $55.12 | 2019-2023 | Veozah |
| Phathom Pharmaceuticals, INC. | $53.53 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $46.47 | 2023-2024 | Yupelri |
| Viatris Specialty LLC | $38.77 | 2025 | Yupelri |
| Aimmune Therapeutics, INC. | $37.97 | 2024-2025 | Zenpep |
| Verona Pharma, INC. | $37.26 | 2025 | Ohtuvayre |
| Nevro Corp. | $36.67 | 2023-2024 | Senza |
| Ardelyx, INC. | $34.71 | 2024 | Ibsrela |
| Globus Medical, INC. | $23.90 | 2025 | Senza |
| Neurocrine Biosciences, INC. | $18.55 | 2024 | Ingrezza |
| Axsome Therapeutics, INC. | $17.44 | 2023 | Auvelity |
| Radius Health, INC. | $15.80 | 2020 | |
| Medtronic, INC. | $14.58 | 2023 | Interstim |
| Genentech USA, INC. | $14.41 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.27 | 2023 | Quviviq |
| Sobi, INC | $12.45 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.26 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Rampton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.